Georgia Wiesner, M.D., M.S.
- Director, Clinical and Translational Hereditary Cancer Program
- Ingram Professor of Cancer Research
- Professor of Medicine
Georgia Wiesner, M.D., M.S.
- Director, Clinical and Translational Hereditary Cancer Program
- Ingram Professor of Cancer Research
- Professor of Medicine
georgia.wiesner@vumc.org
Research Program
Departments/Affiliations
Provider Information
Profile
Dr. Georgia L. Wiesner is an Ingram Professor of Cancer Research, Professor of Medicine in the Division of Genetic Medicine and the Director of the new Clinical and Translational Hereditary Cancer Program for the Vanderbilt-Ingram Cancer Center. As one of the few physicians in the country with dual certification in Internal Medicine and Medical Genetics, Dr. Wiesner has devoted her career to understanding the factors that cause cancer susceptibility. Since joining the Vanderbilt faculty in 2012, she has established a comprehensive Hereditary Cancer Clinic and research program for patients and family members who are prone to develop cancer.
Dr. Wiesner has a long-standing research interest in hereditary cancer susceptibility mainly focused on colon cancer and is also studying how genetic tests are used in clinical medicine as well as various ethical, legal and social aspects of genomic medicine. She established the Hereditary Cancer Registry in 2015 that collects clinical information, genetic testing and research testing on patients and their family members. In the future, the registry will also develop a new cancer risk prediction program that will exploit efforts in electronic family history taking and related strategies in precision medicine. This approach will help to identify Vanderbilt patients at higher cancer risk, so that these patients can be informed about the appropriate screening and other treatment options. In addition, Dr. Wiesner has established VICC as a research site along with Dana Farber in a pilot multi-centered study of lung cancer.
Dr. Wiesner is a current member of the Genetic/Familial High Risk Assessment, Breast & Ovarian Panel of the National Comprehensive Cancer Network (NCCN).This committee provides expert opinion in formulating guidelines for care of patient and families with heritable cancer syndromes. Her previous service includes the Editor-in-Chief of the Cancer Genetics PDQ Editorial Board at the National Cancer Institute from 2001 to 2005, and the Board of Directors for the American Society of Human Genetics, a past- President of the Board of Directors of the American Board of Medical Genetics and past-Chair of the Residency Review Committee for Medical Genetics (ACGME).
Prior to establishing her research programs at Vanderbilt, Dr. Wiesner served in several leadership capacities at Case-Western Reserve University (CWRU) and University Hospitals of Cleveland. She was the Director of the Center for Human Genetics from 2000 to 2008, Medical Director of the Clinical Cancer Genetics program from 1995 to 2012, and founded the first specialized clinic for delivery of genetic services to patients and families with hereditary cancer susceptibility in Northeastern Ohio.
Education
- M.D., University of Minnesota, Minneapolis, Minnesota (1985)
- M.S., University of Minnesota,Minneapolis, Minnesota (1981)
- Internal Medicine Residency, University of Minnesota Medical Center (1988)
- Chief Internal Medicine Resident, University of Minnesota Medical Center (1989)
- Medical Genetics Fellowship, University of Minnesota Medical Center (1992)
Research Emphasis
Research Description
Publications
- Schneider JL, Davis J, Kauffman TL, Reiss JA, McGinley C, Arnold K, Zepp J, Gilmore M, Muessig KR, Syngal S, Acheson L, Wiesner GL, Peterson SK, Goddard KA. Stakeholder perspectives on implementing a universal Lynch syndrome screening program: a qualitative study of early barriers and facilitators. Genet. Med [print-electronic]. 2016 Feb; 18(2): 152-61. PMID: 25880440, PMCID: PMC4608844, PII: gim201543, DOI: 10.1038/gim.2015.43, ISSN: 1530-0366.
- Daly MB, Pilarski R, Axilbund JE, Berry M, Buys SS, Crawford B, Farmer M, Friedman S, Garber JE, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Rana H, Reiser G, Robson ME, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wick MJ, Wiesner GL, Dwyer M, Kumar R, Darlow S. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015. J Natl Compr Canc Netw. 2016 Feb; 14(2): 153-62. PMID: 26850485, PII: 14/2/153, ISSN: 1540-1413.
- Hunter JE, Zepp JM, Gilmore MJ, Davis JV, Esterberg EJ, Muessig KR, Peterson SK, Syngal S, Acheson LS, Wiesner GL, Reiss JA, Goddard KA. Universal tumor screening for Lynch syndrome: Assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers. Cancer [print-electronic]. 2015 Sep 9/15/2015; 121(18): 3281-9. PMID: 26036338, PMCID: PMC4560979, DOI: 10.1002/cncr.29470, ISSN: 1097-0142.
- Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL, . A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet. Med [print-electronic]. 2015 Jan; 17(1): 70-87. PMID: 25394175, PII: gim2014147, DOI: 10.1038/gim.2014.147.
- Hall MJ, Forman AD, Pilarski R, Wiesner G, Giri VN. Gene panel testing for inherited cancer risk. J Natl Compr Canc Netw. 2014 Sep; 12(9): 1339-46. PMID: 25190699, PII: 12/9/1339, ISSN: 1540-1413.
- Daly MB, Pilarski R, Axilbund JE, Buys SS, Crawford B, Friedman S, Garber JE, Horton C, Kaklamani V, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Pasche B, Reiser G, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wiesner GL, Dwyer MA, Kumar R, . Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. J Natl Compr Canc Netw. 2014 Sep; 12(9): 1326-38. PMID: 25190698, PII: 12/9/1326.
- Guda K, Fink SP, Milne GL, Molyneaux N, Ravi L, Lewis SM, Dannenberg AJ, Montgomery CG, Zhang S, Willis J, Wiesner GL, Markowitz SD. Inactivating mutation in the prostaglandin transporter gene, SLCO2A1, associated with familial digital clubbing, colon neoplasia, and NSAID resistance. Cancer Prev Res (Phila) [print-electronic]. 2014 Aug; 7(8): 805-12. PMID: 24838973, PMCID: PMC4125515, PII: 1940-6207.CAPR-14-0108, DOI: 10.1158/1940-6207.CAPR-14-0108, ISSN: 1940-6215.
- Edwards KL, Lemke AA, Trinidad SB, Lewis SM, Starks H, Snapinn KW, Griffin MQ, Wiesner GL, Burke W, . Genetics researchers' and IRB professionals' attitudes toward genetic research review: a comparative analysis. Genet. Med [print-electronic]. 2012 Feb; 14(2): 236-42. PMID: 22241102, PMCID: PMC3448270, PII: gim201157, DOI: 10.1038/gim.2011.57, ISSN: 1530-0366.
- Dressler LG, Smolek S, Ponsaran R, Markey JM, Starks H, Gerson N, Lewis S, Press N, Juengst E, Wiesner GL, . IRB perspectives on the return of individual results from genomic research. Genet. Med [print-electronic]. 2012 Feb; 14(2): 215-22. PMID: 22241094, PMCID: PMC3493147, PII: gim201110, DOI: 10.1038/gim.2011.10, ISSN: 1530-0366.
- Gray-McGuire C, Guda K, Adrianto I, Lin CP, Natale L, Potter JD, Newcomb P, Poole EM, Ulrich CM, Lindor N, Goode EL, Fridley BL, Jenkins R, Le Marchand L, Casey G, Haile R, Hopper J, Jenkins M, Young J, Buchanan D, Gallinger S, Adams M, Lewis S, Willis J, Elston R, Markowitz SD, Wiesner GL. Confirmation of linkage to and localization of familial colon cancer risk haplotype on chromosome 9q22. Cancer Res [print-electronic]. 2010 Jul 7/1/2010; 70(13): 5409-18. PMID: 20551049, PMCID: PMC2896448, PII: 0008-5472.CAN-10-0188, DOI: 10.1158/0008-5472.CAN-10-0188, ISSN: 1538-7445.
